1MIRM : FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder...
Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.
News Medical11h
Antioxidant-enzyme interactions and their role in non-communicable diseases
Oxidative stress, caused by an imbalance between reactive oxygen species (ROS) and antioxidant defenses, plays a central role ...
FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease
Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very ...
Packing lipid nanoparticles with tumor proteins to boost cancer vaccine potency
The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, ...
Scientists Just Found a Cholesterol Clue That Could Change Parkinson’s Treatment
A breakthrough study has uncovered a hidden player in Parkinson’s disease—24-OHC, a cholesterol metabolite that fuels the ...
Chewing jeera vs drinking jeera water: Which is healthier?
Jeera, a staple spice in Indian kitchens, offers numerous health benefits due to its rich nutrient content and bioactive ...